Leadsynbio applies synthetic biology to transform production of chemical and biological products across pharmaceuticals, health products, and agriculture. The company maintains a comprehensive synthetic biology technology platform and R&D team of more than 100 people. It has R&D centers in Suzhou Industrial Park and San Francisco and an industrialization base in Changde, Hunan. Leadsynbio has developed more than 20 new products in its pipeline and has already achieved pilot/patch production for several products using its green technologies. Management says it will use new funding to accelerate commercialization, further improve the R&D pipeline, and expand the Hunan production base. Founder and CEO Dr. Xie Xinkai, with nearly 20 years of experience and recognition for biosynthesis work, leads the company’s industrialization and platform efforts.

Total raised

$63M

Funding rounds

1

Latest round

Series C

Latest activity

Mar 2022